SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: Biomaven who wrote (23712)5/21/2007 3:59:26 PM
From: A.J. Mullen  Respond to of 52153
 
Thanks Peter, you make the CMS decision seem reasonable. I thought Xopenex was clearly superior to racemic albuterol, but a quick Google confirms that this is not generally accepted.

I should have had a clearer idea, given that at one time Sepracor was one of my larger holdings. I sold some, but most of the reduction has been organic decay to where I usually get out or double down. I bought some on Friday.

Ashley


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News